Minerva Neurosciences (NERV) Non-Current Assets (2013 - 2026)
Minerva Neurosciences (NERV) reported Non-Current Assets of $14.9 million for Q1 2026, little changed on a YoY basis from $14.9 million in Q1 2025, and little changed quarter-over-quarter from $14.9 million in Q4 2025.
Minerva Neurosciences (NERV) Non-Current Assets (2013 - 2026) Analysis & Trends
Minerva Neurosciences has reported Non-Current Assets for 14 years, with the latest figure at $14.9 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets changed 0.32% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $59.7 million (changed 0.38% YoY), and the FY2025 full-year result was $14.9 million, changed 0.04% from the prior year.
- Non-Current Assets for Q1 2026 stood at $14.9 million, roughly flat from $14.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $15.1 million in Q3 2025, with the low at $14.9 million in Q4 2025.
- Historically, Non-Current Assets has averaged $14.9 million across 5 years, with a median of $14.9 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 50.5% — and 2025, when it rose 1.32%.
- Minerva Neurosciences' Non-Current Assets stood at $14.9 million in 2022, then slipped by 0.21% to $14.9 million in 2023, then retreated by 0.15% to $14.9 million in 2024, then retreated by 0.04% to $14.9 million in 2025, then increased by 0.34% to $14.9 million in 2026.
- The last three Non-Current Assets figures came in at $14.9 million (Q1 2026), $14.9 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - | 14.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.92 Mn |
| Dec 31, 2025 | 14.87 Mn |
| Sep 30, 2025 | 15.07 Mn |
| Jun 30, 2025 | 14.87 Mn |
| Mar 31, 2025 | 14.87 Mn |
| Dec 31, 2024 | 14.87 Mn |
| Sep 30, 2024 | 14.88 Mn |
| Jun 30, 2024 | 14.88 Mn |
| Mar 31, 2024 | 14.89 Mn |
| Dec 31, 2023 | 14.90 Mn |
| Sep 30, 2023 | 14.91 Mn |
| Jun 30, 2023 | 14.91 Mn |
| Mar 31, 2023 | 14.92 Mn |
| Dec 31, 2022 | 14.93 Mn |
| Sep 30, 2022 | 14.92 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 14.92 Mn |
| Dec 31, 2021 | 14.92 Mn |
| Sep 30, 2021 | 30.12 Mn |
| Jun 30, 2021 | 30.10 Mn |